McNeill Roisin E, Miller Nicola, Kerin Michael J
Department of Surgery, Clinical Science Institute, National University of Ireland, Galway, Ireland.
BMC Mol Biol. 2007 Nov 27;8:107. doi: 10.1186/1471-2199-8-107.
Real-time quantitative PCR (RQ-PCR) forms the basis of many breast cancer biomarker studies and novel prognostic assays, paving the way towards personalised cancer treatments. Normalisation of relative RQ-PCR data is required to control for non-biological variation introduced during sample preparation. Endogenous control (EC) genes, used in this context, should ideally be expressed constitutively and uniformly across treatments in all test samples. Despite widespread recognition that the accuracy of the normalised data is largely dependent on the reliability of the EC, there are no reports of the systematic validation of genes commonly used for this purpose in the analysis of gene expression by RQ-PCR in primary breast cancer tissues. The aim of this study was to identify the most suitable endogenous control genes for RQ-PCR analysis of primary breast tissue from a panel of eleven candidates in current use. Oestrogen receptor alpha (ESR1) was used a target gene to compare the effect of choice of EC on the estimate of gene quantity.
The expression and validity of candidate ECs (GAPDH, TFRC, ABL, PPIA, HPRT1, RPLP0, B2M, GUSB, MRPL19, PUM1 and PSMC4) was determined in 6 benign and 21 malignant primary breast cancer tissues. Gene expression data was analysed using two different statistical models. MRPL19 and PPIA were identified as the most stable and reliable EC genes, while GUSB, RPLP0 and ABL were least stable. There was a highly significant difference in variance between ECs. ESR1 expression was appreciably higher in malignant compared to benign tissues and there was a significant effect of EC on the magnitude of the error associated with the relative quantity of ESR1.
We have validated two endogenous control genes, MRPL19 and PPIA, for RQ-PCR analysis of gene expression in primary breast tissue. Of the genes in current use in this field, the above combination offers increased accuracy and resolution in the quantitation of gene expression data, facilitating the detection of smaller changes in gene expression than otherwise possible. The combination identified here is a good candidate for use as a two-gene endogenous control in a broad spectrum of future research and diagnostic applications in breast cancer.
实时定量聚合酶链反应(RQ-PCR)构成了许多乳腺癌生物标志物研究和新型预后分析的基础,为个性化癌症治疗铺平了道路。相对RQ-PCR数据的标准化是必要的,以控制样品制备过程中引入的非生物学变异。在此背景下使用的内参(EC)基因理想情况下应在所有测试样品的各种处理中组成性且均匀地表达。尽管人们普遍认识到标准化数据的准确性在很大程度上取决于内参的可靠性,但尚无关于在原发性乳腺癌组织中通过RQ-PCR分析基因表达时常用作此目的的基因进行系统验证的报道。本研究的目的是从当前使用的一组11个候选基因中确定用于原发性乳腺组织RQ-PCR分析的最合适内参基因。雌激素受体α(ESR1)用作靶基因,以比较内参选择对基因量估计的影响。
在6例良性和21例恶性原发性乳腺癌组织中测定了候选内参基因(GAPDH、TFRC、ABL、PPIA、HPRT1、RPLP0、B2M、GUSB、MRPL19、PUM1和PSMC4)的表达及有效性。使用两种不同的统计模型分析基因表达数据。MRPL19和PPIA被确定为最稳定可靠的内参基因,而GUSB、RPLP0和ABL最不稳定。内参基因之间的方差存在极显著差异。与良性组织相比,恶性组织中ESR1表达明显更高,并且内参对与ESR1相对量相关的误差大小有显著影响。
我们已经验证了两个内参基因MRPL19和PPIA用于原发性乳腺组织基因表达的RQ-PCR分析。在该领域目前使用的基因中,上述组合在基因表达数据定量方面提供了更高的准确性和分辨率,有助于检测比其他情况可能更小的基因表达变化。此处确定的组合是在未来广泛的乳腺癌研究和诊断应用中用作双基因内参的良好候选者。